Acumen Pharmaceuticals (NASDAQ: ABOS) refreshes Alzheimer’s pipeline and EBD data deck

Rhea-AI Filing Summary

Acumen Pharmaceuticals, Inc. filed a current report to highlight that it has posted an updated corporate presentation on its investor website. The presentation now includes nonclinical murine brain exposure data supporting its Enhanced Brain Delivery (EBD™) program that was presented at the 2025 Clinical Trials on Alzheimer’s Disease conference, updated views of previously presented fluid biomarker data from its Phase 1 INTERCEPT-AD study, and the addition of ACU234 to the company’s pipeline in connection with the EBD program. The presentation is furnished as Exhibit 99.1 and, along with this disclosure, is designated as furnished rather than filed under securities law.

0001576885FALSE1210-1220 Washington StreetSuite 210NewtonMassachusetts00015768852026-01-122026-01-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

____________________________

FORM 8-K

____________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 12, 2026

____________________________

Acumen Pharmaceuticals, Inc.

(Exact name of Registrant as Specified in Its Charter)

____________________________

Delaware			001-40551			36-4108129
(State or Other Jurisdiction of Incorporation)			(Commission File Number)			(IRS Employer Identification No.)

1210-1220 Washington Street, Suite 210 Newton, Massachusetts			02465
(Address of Principal Executive Offices)			(Zip Code)

(617) 344-4190

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

____________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

o			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.0001 par value

ABOS

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  o

Item 7.01     Regulation FD Disclosure.

On January 12, 2026, Acumen Pharmaceuticals, Inc. (the “Company”) posted an updated corporate presentation to its website at https://investors.acumenpharm.com/news-events/presentations, which the Company may use from time to time in communications or conferences. The corporate presentation was updated to reflect the inclusion of nonclinical murine brain exposure data supporting our Enhanced Brain Delivery (EBD™) program that was presented at Clinical Trials on Alzheimer’s Disease (“CTAD”) conference 2025, updated views of previously presented fluid biomarker data associated with our Phase 1 INTERCEPT-AD study, and the inclusion of ACU234 in the pipeline related to our EBD program. A copy of the corporate presentation is attached as Exhibit 99.1 to this Report.

The information in this Item 7.01 of this Report (including Exhibit 99.1), is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing. The Company’s submission of this Report shall not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.

Item 9.01    Financial Statements and Exhibits.

(d).Exhibits

Exhibit No.						Description
99.1						Corporate Presentation, dated January 12, 2026
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Acumen Pharmaceuticals, Inc.
Dated: January 12, 2026			By:			/s/ Derek Meisner
						Derek Meisner Chief Legal Officer

FAQ

What did Acumen Pharmaceuticals (ABOS) disclose in this Form 8-K?

Acumen Pharmaceuticals reported that it posted an updated corporate presentation on its investor website and furnished that presentation as Exhibit 99.1.

What new information is included in Acumen Pharmaceuticals’ updated corporate presentation?

The presentation adds nonclinical murine brain exposure data for the Enhanced Brain Delivery (EBD™) program, updated fluid biomarker views from the Phase 1 INTERCEPT-AD study, and includes ACU234 in the EBD-related pipeline.

Where can investors find Acumen Pharmaceuticals’ updated corporate presentation?

Investors can access the updated presentation at https://investors.acumenpharm.com/news-events/presentations, as noted in the disclosure.

How is the information in the Acumen Pharmaceuticals 8-K treated under securities laws?

The company states that the information in Item 7.01, including Exhibit 99.1, is being furnished, not filed, and is not subject to Section 18 liability or automatically incorporated into other filings unless specifically referenced.

What is ACU234 in the context of Acumen Pharmaceuticals’ pipeline?

ACU234 is identified as a program included in the company’s pipeline related to its Enhanced Brain Delivery (EBD™) program, as shown in the updated corporate presentation.

Which Acumen Pharmaceuticals study’s data was updated in the presentation?

The company notes updated views of previously presented fluid biomarker data from its Phase 1 INTERCEPT-AD study.